Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo‐controlled cross‐over study
- 17 September 2018
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (3) , 509-516
Abstract
Aim: To investigate whether mineralocorticoid (MC) antagonism enhances brown adipose tissue (BAT) function in humans. Materials and Methods: In a randomized double‐blind, cross‐over designed trial, 10 healthy adults (two men, eight women) underwent 2 weeks of spironolactone (100 mg/d) treatment and placebo, with an intervening 2‐week wash‐out period. BAT function was assessed in response to cooling and to a mixed meal. Metabolic activity was measured by fluoro‐deoxyglucose (FDG) uptake (maximal standardized uptake value, SUV max ) using PET‐CT. Thermogenic activity was measured by skin temperatures overlying supraclavicular (SCL) BAT depots using infrared thermography. Postprandial metabolism was measured by energy production rate (EPR) and lipid synthesis using indirect calorimetry. Results: During cooling, BAT metabolic activity (SUV 6.30 ± 2.16 vs 3.98 ± 1.34; P < 0.05) and volume (54.9 ± 22.8 vs 21.6 ± 11.8 cm 3 ; P < 0.05) were significantly higher, and mean SCL temperature decreased by a smaller degree (−0.3°C°± 0.2°C vs −0.9°C ± 0.2°C; P = 0.05) with spironolactone treatment. A mixed meal increased SCL temperature and EPR. The postprandial rise in SCL temperature (+0.4°C ± 0.1°C vs +0.1°C ± 0.1°C; P < 0.05) but not in EPR was greater during spironolactone treatment. Postprandial lipid synthesis occurred in three participants with placebo but in none with spironolactone treatment ( P = 0.06). Conclusion: MC antagonism enhanced human BAT function in response to cooling and to a meal during which lipid synthesis was suppressed. As postprandial EPR comprises energy dissipated as heat and energy required to store nutrients, the reduction in lipid synthesis during MC antagonism is a probable consequence of concurrent stimulation of BAT thermogenesis. The shift in energy usage from storage to heat dissipation indicates that MC antagonists may have therapeutic benefit for obesity.Keywords
Funding Information
- Princess Alexandra Hospital Research Support Scheme
- Pathology Queensland
This publication has 34 references indexed in Scilit:
- Cold acclimation recruits human brown fat and increases nonshivering thermogenesisJournal of Clinical Investigation, 2013
- Recruited brown adipose tissue as an antiobesity agent in humansJournal of Clinical Investigation, 2013
- Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humansJournal of Clinical Investigation, 2012
- Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adultsEuropean Journal of Endocrinology, 2010
- Androgens and metabolic syndrome: Lessons from androgen receptor knock out (ARKO) miceThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational studyJournal Of Hypertension, 2007
- Plasma Aldosterone Is Independently Associated With the Metabolic SyndromeHypertension, 2006
- Aldosterone Inhibits Uncoupling Protein-1, Induces Insulin Resistance, and Stimulates Proinflammatory Adipokines in AdipocytesHormone and Metabolic Research, 2005
- The evolution of aldosterone antagonistsMolecular and Cellular Endocrinology, 2004
- Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action.Journal of Clinical Investigation, 1998